Patient characteristics, stratified on cohort (EHR or population) and period of COVID-19+ test
| . | Period 1 . | Period 2 . | Period 3 . | Period 4 . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate . | EHR (n = 59) . | Population (n = 24) . | EHR (n = 40) . | Population (n = 66) . | EHR (n = 32) . | Population (n = 73) . | EHR (n = 22) . | Population (n = 477) . | Total (n = 793) . | P value . | |
| Age at PCR | Median [IQR] | 71 [64.5, 80.5] | 70.5 [54.2, 74.5] | 77 [68.2, 82.0] | 70 [62, 78] | 74.5 [69.8, 83.0] | 70 [63, 77] | 76 [72.0, 80.5] | 72 [64, 77] | 72 [64, 78] | .0052 |
| Sex | Female | 27 (45.8) | 7 (29.2) | 17 (42.5) | 24 (36.4) | 12 (37.5) | 29 (39.7) | 9 (40.9) | 181 (37.9) | 306 (38.6) | |
| Male | 32 (54.2) | 17 (70.8) | 23 (57.5) | 42 (63.6) | 20 (62.5) | 44 (60.3) | 13 (59.1) | 296 (62.1) | 487 (61.4) | .91 | |
| CLL diagnosis | Median [IQR] | 2017 [2012, 2019] | 2015 [2012, 2016] | 2015 [2010, 2018] | 2015 [2013, 2016] | 2016 [2014, 2018] | 2015 [2013, 2017] | 2017 [2014, 2018] | 2015 [2012, 2017] | 2015 [2012, 2017] | .024 |
| Missing | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | ||
| Binet stage | A | 34 (87.2) | 20 (83.3) | 22 (75.9) | 57 (86.4) | 21 (95.5) | 69 (94.5) | 14 (73.7) | 402 (84.3) | 639 (85.3) | |
| B | 3 (7.7) | 2 (8.3) | 6 (20.7) | 7 (10.6) | 1 (4.5) | 4 (5.5) | 3 (15.8) | 65 (13.6) | 91 (12.1) | ||
| C | 2 (5.1) | 2 (8.3) | 1 (3.4) | 2 (3.0) | 0 (0.0) | 0 (0.0) | 2 (10.5) | 10 (2.1) | 19 (2.5) | .097 | |
| Missing | 20 | 0 | 11 | 0 | 10 | 0 | 3 | 0 | 44 | ||
| IGHV status | Unmutated | 8 (28.6) | 6 (33.3) | 9 (39.1) | 18 (33.3) | 6 (40.0) | 19 (33.9) | 3 (20.0) | 105 (27.0) | 174 (29.1) | |
| Mutated | 20 (71.4) | 12 (66.7) | 14 (60.9) | 36 (66.7) | 9 (60.0) | 37 (66.1) | 12 (80.0) | 284 (73.0) | 424 (70.9) | .70 | |
| Missing | 31 | 6 | 17 | 12 | 17 | 17 | 7 | 88 | 195 | ||
| FISH status | Del13q | 18 (64.3) | 11 (64.7) | 10 (43.5) | 28 (54.9) | 9 (50.0) | 34 (61.8) | 7 (46.7) | 221 (61.6) | 338 (59.7) | |
| Normal | 3 (10.7) | 1 (5.9) | 4 (17.4) | 9 (17.6) | 0 (0.0) | 9 (16.4) | 1 (6.7) | 44 (12.3) | 71 (12.5) | ||
| Tri12 | 4 (14.3) | 3 (17.6) | 3 (13.0) | 6 (11.8) | 5 (27.8) | 9 (16.4) | 3 (20.0) | 53 (14.8) | 86 (15.2) | ||
| Del11q | 1 (3.6) | 1 (5.9) | 3 (13.0) | 5 (9.8) | 2 (11.1) | 3 (5.5) | 3 (20.0) | 24 (6.7) | 42 (7.4) | ||
| Del17p | 2 (7.1) | 1 (5.9) | 3 (13.0) | 3 (5.9) | 2 (11.1) | 0 (0.0) | 1 (6.7) | 17 (4.7) | 29 (5.1) | .68 | |
| Missing | 31 | 7 | 17 | 15 | 14 | 18 | 7 | 118 | 227 | ||
| Admission | Yes | 41 (69.5) | NA | 33 (82.5) | NA | 19 (59.4) | NA | 12 (54.5) | NA | 105 (68.6) | |
| No | 18 (30.5) | NA | 7 (17.5) | NA | 13 (40.6) | NA | 10 (45.5) | NA | 48 (31.4) | .075 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| ICU | Yes | 7 (11.9) | NA | 5 (12.5) | NA | 1 (3.1) | NA | 0 (0.0) | NA | 13 (8.5) | |
| No | 52 (88.1) | NA | 35 (87.5) | NA | 31 (96.9) | NA | 22 (100.0) | NA | 140 (91.5) | .26 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| Died | Yes | 10 (16.9) | 0 (0.0) | 7 (17.5) | 4 (6.1) | 3 (9.4) | 4 (5.5) | 5 (22.7) | 4 (0.8) | 37 (4.7) | |
| No | 49 (83.1) | 24 (100.0) | 33 (82.5) | 62 (93.9) | 29 (90.6) | 69 (94.5) | 17 (77.3) | 473 (99.2) | 756 (95.3) | <.0001 | |
| Dexa-methasone | Yes | 11 (18.6) | NA | 16 (40.0) | NA | 9 (28.1) | NA | 4 (18.2) | NA | 40 (26.1) | |
| No | 48 (81.4) | NA | 24 (60.0) | NA | 23 (71.9) | NA | 18 (81.8) | NA | 113 (73.9) | .090 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| Remdesivir | Yes | 12 (20.3) | NA | 18 (45.0) | NA | 8 (25.0) | NA | 3 (13.6) | NA | 41 (26.8) | |
| No | 47 (79.7) | NA | 22 (55.0) | NA | 24 (75.0) | NA | 19 (86.4) | NA | 112 (73.2) | .019 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| mAb | Yes | 0 (0.0) | NA | 10 (25.0) | NA | 12 (37.5) | NA | 8 (36.4) | NA | 30 (19.6) | |
| No | 59 (100.0) | NA | 30 (75.0) | NA | 20 (62.5) | NA | 14 (63.6) | NA | 123 (80.4) | <.0001 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| . | Period 1 . | Period 2 . | Period 3 . | Period 4 . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariate . | EHR (n = 59) . | Population (n = 24) . | EHR (n = 40) . | Population (n = 66) . | EHR (n = 32) . | Population (n = 73) . | EHR (n = 22) . | Population (n = 477) . | Total (n = 793) . | P value . | |
| Age at PCR | Median [IQR] | 71 [64.5, 80.5] | 70.5 [54.2, 74.5] | 77 [68.2, 82.0] | 70 [62, 78] | 74.5 [69.8, 83.0] | 70 [63, 77] | 76 [72.0, 80.5] | 72 [64, 77] | 72 [64, 78] | .0052 |
| Sex | Female | 27 (45.8) | 7 (29.2) | 17 (42.5) | 24 (36.4) | 12 (37.5) | 29 (39.7) | 9 (40.9) | 181 (37.9) | 306 (38.6) | |
| Male | 32 (54.2) | 17 (70.8) | 23 (57.5) | 42 (63.6) | 20 (62.5) | 44 (60.3) | 13 (59.1) | 296 (62.1) | 487 (61.4) | .91 | |
| CLL diagnosis | Median [IQR] | 2017 [2012, 2019] | 2015 [2012, 2016] | 2015 [2010, 2018] | 2015 [2013, 2016] | 2016 [2014, 2018] | 2015 [2013, 2017] | 2017 [2014, 2018] | 2015 [2012, 2017] | 2015 [2012, 2017] | .024 |
| Missing | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | ||
| Binet stage | A | 34 (87.2) | 20 (83.3) | 22 (75.9) | 57 (86.4) | 21 (95.5) | 69 (94.5) | 14 (73.7) | 402 (84.3) | 639 (85.3) | |
| B | 3 (7.7) | 2 (8.3) | 6 (20.7) | 7 (10.6) | 1 (4.5) | 4 (5.5) | 3 (15.8) | 65 (13.6) | 91 (12.1) | ||
| C | 2 (5.1) | 2 (8.3) | 1 (3.4) | 2 (3.0) | 0 (0.0) | 0 (0.0) | 2 (10.5) | 10 (2.1) | 19 (2.5) | .097 | |
| Missing | 20 | 0 | 11 | 0 | 10 | 0 | 3 | 0 | 44 | ||
| IGHV status | Unmutated | 8 (28.6) | 6 (33.3) | 9 (39.1) | 18 (33.3) | 6 (40.0) | 19 (33.9) | 3 (20.0) | 105 (27.0) | 174 (29.1) | |
| Mutated | 20 (71.4) | 12 (66.7) | 14 (60.9) | 36 (66.7) | 9 (60.0) | 37 (66.1) | 12 (80.0) | 284 (73.0) | 424 (70.9) | .70 | |
| Missing | 31 | 6 | 17 | 12 | 17 | 17 | 7 | 88 | 195 | ||
| FISH status | Del13q | 18 (64.3) | 11 (64.7) | 10 (43.5) | 28 (54.9) | 9 (50.0) | 34 (61.8) | 7 (46.7) | 221 (61.6) | 338 (59.7) | |
| Normal | 3 (10.7) | 1 (5.9) | 4 (17.4) | 9 (17.6) | 0 (0.0) | 9 (16.4) | 1 (6.7) | 44 (12.3) | 71 (12.5) | ||
| Tri12 | 4 (14.3) | 3 (17.6) | 3 (13.0) | 6 (11.8) | 5 (27.8) | 9 (16.4) | 3 (20.0) | 53 (14.8) | 86 (15.2) | ||
| Del11q | 1 (3.6) | 1 (5.9) | 3 (13.0) | 5 (9.8) | 2 (11.1) | 3 (5.5) | 3 (20.0) | 24 (6.7) | 42 (7.4) | ||
| Del17p | 2 (7.1) | 1 (5.9) | 3 (13.0) | 3 (5.9) | 2 (11.1) | 0 (0.0) | 1 (6.7) | 17 (4.7) | 29 (5.1) | .68 | |
| Missing | 31 | 7 | 17 | 15 | 14 | 18 | 7 | 118 | 227 | ||
| Admission | Yes | 41 (69.5) | NA | 33 (82.5) | NA | 19 (59.4) | NA | 12 (54.5) | NA | 105 (68.6) | |
| No | 18 (30.5) | NA | 7 (17.5) | NA | 13 (40.6) | NA | 10 (45.5) | NA | 48 (31.4) | .075 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| ICU | Yes | 7 (11.9) | NA | 5 (12.5) | NA | 1 (3.1) | NA | 0 (0.0) | NA | 13 (8.5) | |
| No | 52 (88.1) | NA | 35 (87.5) | NA | 31 (96.9) | NA | 22 (100.0) | NA | 140 (91.5) | .26 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| Died | Yes | 10 (16.9) | 0 (0.0) | 7 (17.5) | 4 (6.1) | 3 (9.4) | 4 (5.5) | 5 (22.7) | 4 (0.8) | 37 (4.7) | |
| No | 49 (83.1) | 24 (100.0) | 33 (82.5) | 62 (93.9) | 29 (90.6) | 69 (94.5) | 17 (77.3) | 473 (99.2) | 756 (95.3) | <.0001 | |
| Dexa-methasone | Yes | 11 (18.6) | NA | 16 (40.0) | NA | 9 (28.1) | NA | 4 (18.2) | NA | 40 (26.1) | |
| No | 48 (81.4) | NA | 24 (60.0) | NA | 23 (71.9) | NA | 18 (81.8) | NA | 113 (73.9) | .090 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| Remdesivir | Yes | 12 (20.3) | NA | 18 (45.0) | NA | 8 (25.0) | NA | 3 (13.6) | NA | 41 (26.8) | |
| No | 47 (79.7) | NA | 22 (55.0) | NA | 24 (75.0) | NA | 19 (86.4) | NA | 112 (73.2) | .019 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
| mAb | Yes | 0 (0.0) | NA | 10 (25.0) | NA | 12 (37.5) | NA | 8 (36.4) | NA | 30 (19.6) | |
| No | 59 (100.0) | NA | 30 (75.0) | NA | 20 (62.5) | NA | 14 (63.6) | NA | 123 (80.4) | <.0001 | |
| Missing | 0 | 24 | 0 | 66 | 0 | 73 | 0 | 477 | 640 | ||
Period 1: 12 March and 16 September 2020 for EHR and population cohorts, respectively, to 31 December 2020; period 2: January 2021 to 25 November 2021; period 3: 26 November 2021 to December 2021; and period 4: 1 January 2022 to 28 January 2022 and 7 March 2022 for EHR and population cohorts, respectively. Data on monoclonal antibodies against COVID-19 (mAb), remdesivir, and dexamethasone treatment upon COVID-19 for the different time periods were only available for the EHR cohort. Continuous variables summarized with median and interquartile range (IQR) were tested using Kruskal-Wallis tests, whereas categorical variables summarized by count (percentage) were tested using χ-square tests for differences across all 8 subgroups. P values were calculated using the log-rank test.